PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition
Bob Meeusen, Emanuela Elsa Cortesi, Judit Domènech Omella, Anna Sablina, Juan‐José Ventura, Veerle Janssens
Topics & Concepts
KRASCancer researchSelumetinibBiologyAdenocarcinomaCarcinogenesisPI3K/AKT/mTOR pathwayLung cancerTargeted therapyMutantCancerMedicineSignal transductionPathologyCell biologyGeneGeneticsColorectal cancerProtein Tyrosine PhosphatasesPI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations